InspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?

Key Points

• InspireMD shares rose 3.5% to about $1.18 (intraday high $1.2399) on Thursday with volume of 69,700 shares, a 73% increase versus the average session volume.
• Three analysts currently rate the stock Buy with an average price target of $5.00, implying significant upside from the current price.
• InspireMD is a medical device company known for its MicroNet® mesh and the CGuard® Embolic Prevention System, which has CE Mark approval and is commercially available in multiple international markets.

InspireMD, Inc. (NYSE:NSPR - Get Free Report)'s stock price traded up 3.5% on Thursday . The stock traded as high as $1.2399 and last traded at $1.18. 69,700 shares traded hands during trading, an increase of 73% from the average session volume of 40,388 shares. The stock had previously closed at $1.14.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NSPR shares. Maxim Group started coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a "buy" rating and a $6.00 target price for the company. Lake Street Capital restated a "buy" rating on shares of InspireMD in a report on Tuesday, February 24th. Finally, Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $5.00.

InspireMD Trading Up 3.5%

The firm's fifty day moving average price is $1.55 and its 200-day moving average price is $1.78. The firm has a market cap of $55.33 million, a price-to-earnings ratio of -1.57 and a beta of 0.95.

Institutional Trading of InspireMD

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in InspireMD in the 4th quarter valued at $30,000. Virtu Financial LLC purchased a new stake in InspireMD in the 4th quarter valued at $31,000. Creative Planning purchased a new stake in InspireMD in the 2nd quarter valued at $44,000. Uniting Wealth Partners LLC purchased a new stake in InspireMD in the 3rd quarter valued at $51,000. Finally, Legato Capital Management LLC purchased a new stake in InspireMD in the 4th quarter valued at $48,000. Hedge funds and other institutional investors own 44.78% of the company's stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.